A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases

Inclusion Criteria: * Women or men age ≥18 of age at time of consent. * Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of this study. * Adequate hematological, liver, pulmonary, and cardiac function * Willing to participate to participate in long term follow up study. * Confirmed diagnosis of moderate to severe systemic lupus erythematosus with lupus nephritis, systemic lupus erythematosus with extrarenal lupus, systemic sclerosis, and idiopathic inflammatory myositis. * Failed at least two immunosuppressive treatments Exclusion Criteria: * Inability to tolerate washout of prior therapy. * Not willing/understanding the requirements of the clinical study * Dependent on hemodialysis for a period of greater or equal to 3 months. * Known hypersensitivity to prednisone or to both tocilizumab siltuximab. * Have received plasmapheresis within 14 days prior to informed consent. * Active bacterial, viral and/or fungal infection. * Prior autologous/allogeneic stem cell transplant or solid organ transplant. * Prior lentiviral or retroviral based therapy including CAR-T cell therapy. * History or concurrent malignancy with active treatment in the past 5 years * HIV-1 and HIV-2 antibody positive subjects. * History of central nervous system diseases (such as seizure, psychosis, organic brain syndrome or cerebrovascular accident).